19th April 2022 | Pharma Updates
Rodolfo Hrosz appointed as the India unit head by Sanofi
Sanofi India Limited (SIL) announced today that Rodolfo Hrosz has been appointed as the Company’s new Managing Director, effective June 1, 2022, subject to regulatory approvals.
Lupin rebuked by the FDA at its Indian pharmaceutical ingredients plant
Lupin’s active pharmaceutical ingredient (API) plant in Tarapur, India, has been issued a Form 483, according to a filing (PDF). The FDA issued its findings following a visit to Lupin’s facility from March 22 to April 4.
CCI approves deal for multiple fund III and others to acquire a minority stake in BDR Pharma
The Competition Commission of India (CCI) has approved Multiples Private Equity Fund III and other investors’ acquisition of a minority stake in BDR Pharmaceuticals International (BDR).
Lupin receives Tenofovir Alafenamide Tablets Tentative Approval from US FDA
The US Food and Drug Administration (FDA) has tentatively approved the company’s abbreviated new drug application for Tenofovir Alafenamide tablets (25 mg).
Government looking for innovative products to increase credit flow to pharmaceutical companies
As it seeks to increase credit flow to the pharmaceuticals sector, the government is considering innovative credit products such as funds against intellectual property rights (IPR).
Minister of Industry inspects pharma units in the Baddi-Barotiwala industrial area
Bikram Thakur, Minister of Industry, today inspected four pharmaceutical units in the Baddi-Barotiwala (BB) industrial area and discovered violations of various labour laws.
Amneal Pharmaceuticals' Alymsys (bevacizumab-maly) approved by FDA
Amneal Pharmaceuticals is working on the brand name ALYMSYS, which will be used to market the biosimilar that was approved by the Food and Drug Administration on April 13, 2022.